8 March 2009 in Vox Sanguinis
4 December 2012 in Haemophilia
17 August 2010 in Journal of Thrombosis and Haemostasis
Summary. Background: The clot solubility test is the most widely used method for detection of factor (F)XIII deficiency. However, it will only detect severe deficiencies; consequently mild deficiencies and heterozygous states are probably under diagnosed. Objective: As an alternative first‐line screening test, we assessed an automated quantitative ammonia release assay (QARA). Patients/methods: Inter‐assay imprecision was evaluated with commercial normal and pathological control plasmas (10 replicates on each of 5 days). Using the QARA and other commercial assays a comparative assessment of congenital (FXIII range < 1–70 u dL−1, n = 9) and acquired (n = 43) deficiencies was made. We also investigated the prevalence of acquired deficiencies in hospitalized patients using residual samples from adult patients (n = 1004) and from a paediatric intensive care unit (ICU, n = 56). Results: Assay imprecision was acceptably low (normal control: mean 86.6 u dL−1; cv = 2.0%; pathological control: mean 27.5 u dL−1; cv = 3.8%). Using an iodoacetamide blanking procedure, the QARA results (FXIII range < 1–70 u dL−1) exhibited close agreement with those from an immuno‐turbidometric FXIII A‐subunit (FXIII‐A) method. There was also good correlation (R2 ≥ 0.89) between the QARA (range 20–180 u dL−1), a second chromogenic assay, the FXIII‐A and FXIII A+B‐subunit ELISA. We found that 21% of samples from adult patients had FXIII levels < 70 u dL−1 (mean normal ± 2 SD 73–161 u dL−1) with 6% < 50 u dL−1. Within the paediatric ICU samples, 52% were < 70 u dL−1, with 21% < 50 u dL−1. Conclusions: Our data demonstrates that the automated assay is sensitive, highly reproducible and the results from clinical samples suggest that acquired FXIII deficiency is a relatively common phenomenon in hospital patients after surgery and in ICU.
1 January 1999 in Thrombosis and Haemostasis
This study was undertaken to appraise the application of those reagents most widely used in the UK for the detection and confirmation of lupus anticoagulant (LA) on an Amelung KC4A and a Sysmex CA-6000™ coagulometer. Five sets of dilute Russell’s viper venom time (DRVVT) reagents were assessed as well as the Textarin®-PL/ Ecarin ratio. Each DRVVT method comprised both LA detection and confirmation reagents provided by the same manufacturer. Samples were obtained from 20 normal healthy subjects, 10 LA-positive patients, 10 patients receiving oral anticoagulant therapy (OAT) who had previously been documented as LA-positive, a further 10 LA-negative patients receiving OAT and 10 LA-negative patients receiving unfractionated heparin therapy. The sensitivity and specificity of the reagents exhibited considerable variation not only between reagents, but also when the same reagent was used on the two analysers. Sensitivity ranged from 62 to 97% (all reagents both analysers), specificity went as low as 23% (Gradipore reagent on the CA-6000™) and as high as 100% (American Diagnostica Inc on both KC4A and CA-6000™). On the KC4A instrument, Unicorn Diagnostics’ lupus anticoagulant kit offered the best compromise of sensitivity and specificity (sensitivity 83% and specificity 81%). On the CA-6000™ the reagents supplied by American Diagnostica Inc exhibited optimal performance (sensitivity 90% and specificity 100%). The results indicate a need to optimise test reagents for specific analyser types, a procedure which can only be undertaken with preparations such as the proposed NIBSC reference plasmas for the detection of lupus anticoagulant.
1 December 2000 in British Journal of Haematology
11 September 2008 in Vox Sanguinis